HARVARD BIOSCIENCE INC
Company Information
Industry
Laboratory Analytical Instruments
SIC Code
3826
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
84 OCTOBER HILL RD, HOLLISTON, MA, 01746
Mailing Address
84 OCTOBER HILL ROAD, HOLLISTON, MA, 01746
Phone
5088938999
Fiscal Year End
1231
EIN
043306140
Financial Overview
FY2025
-$12.40M
Net Income
$66.34M
Total Liabilities
$73.07M
Stockholders' Equity
$-0.28
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| 10-K Annual financial report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
Annual Reports
10-K
March 13, 2026
- Harvard Bioscience (HBIO) serves the critical life science research community globally, including drug discovery and preclinical testing.
- The company demonstrates strong regulatory compliance, consistently filing SEC reports and maintaining effective internal controls over financial reporting.
Material Events
8-K
Strategy Change
March 17, 2026
High Impact
- Major strategic pivot to 'pure-play Translational Science Tools' focusing on accelerating drug discovery with human-relevant methods.
- New leadership, including CEO John Duke (July 2025) and CFO Mark Frost (March 2026), and an expanded Board of Directors.
8-K
Strategy Change
March 6, 2026
High Impact
- Ensures continued compliance with Nasdaq's minimum bid price requirement of $1.00 per share, mitigating delisting risk.
- Aims to strengthen the company's market position and improve perception among institutional investors.
Insider Trading
BUY
4 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 3826)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.